TCTR20211014001尚未招募不适用
Real-world use of once-weekly semaglutide in Thai patients with type 2 diabetes mellitus: A retrospective monocentric study in Bangkok
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •Thai patients with T2DM who initiated semaglutide for at least 1 month between 2020 and 2021 at Theptarin Hospital, Bangkok, Thailand
排除标准
- •Non-Thai ethnicity
- •Use semaglutide less than 1 month
研究者
相似试验
招募中
1 期
A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetes (SUSTAIN OPTIMIZE)CTIS2024-510612-75-00ovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesDiabetes Mellitus, type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2021-004392-13-ESovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesDiabetes Mellitus, type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-004392-13-SKovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesDiabetes Mellitus, type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-004392-13-GRovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesEUCTR2021-004392-13-PTovo Nordisk A/S568